drugset / Trial / NCT02397525

An Open-Label Study to Evaluate Retreatment With LIPO-202

NCT02397525

Phase 2 Unknown 150 enrolled Neothetics, Inc
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety of three 8-week courses of treatment with LIPO-202 in non-obese patients who have central abdominal bulging. Efficacy measurements will also be collected.

Timeline

Start
2015-03
Primary completion
2016-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol Other / unclassified